10-Q: Ainos Q3 2025: AI Nose Platform Drives Revenue Amid Losses

Ainos, Inc. reports increased revenue from its AI Nose platform and VELDONA pet supplements in Q3 2025, but faces continued net losses and significant liquidity challenges.

Summary

• Net loss for the three months ended September 30, 2025, decreased by 21% to $(2,931,702) compared to $(3,699,317) in the same period of 2024.
• Net loss for the nine months ended September 30, 2025, increased by 1% to $(10,302,714) from $(10,209,149) in the prior year period.
• Revenue for Q3 2025 was $2,167, up from nil in Q3 2024, primarily from VELDONA pet supplements.
• Revenue for the nine months ended September 30, 2025, increased by 445% to $113,037 from $20,729 in the prior year period, driven by VOC sensing products related to NISD co-development.
• Operating loss decreased by 8% in Q3 2025 to $(2,784,193) but increased by 5% for the nine months to $(9,692,751).
• Cash and cash equivalents stood at $1,128,217 as of September 30, 2025, a significant decrease from $3,892,919 at December 31, 2024.
• The company completed a 1-for-5 reverse stock split on June 30, 2025, to comply with Nasdaq's minimum $1.00 per share continued listing rules.
• Ainos is focusing on commercializing its AI Nose platform in industrial, robotics, and long-term care settings through strategic partnerships and a subscription-based model.
• The company continues to develop VELDONA low-dose oral interferon therapeutics and POCT products, with clinical studies underway in Taiwan for several indications.

Sentiment

Score: 3

Explanation: While the company shows promising revenue growth from its AI Nose platform and VELDONA pet supplements, and has secured strategic partnerships, its overall financial health remains precarious with increasing net losses over nine months, a significant decline in cash reserves, and an explicit 'going concern' warning. The repeated reverse stock splits also signal underlying issues.

Positives

• Significant revenue growth in Q3 2025 (from nil to $2,167) and for the nine months ended September 30, 2025 (445% increase to $113,037), driven by VELDONA pet supplements and VOC sensing products.
• Net loss decreased by 21% in Q3 2025 compared to Q3 2024, from $(3,699,317) to $(2,931,702).
• Operating loss decreased by 8% in Q3 2025, from $(3,038,549) to $(2,784,193).
• Successful execution of an At-the-Market (ATM) offering, raising $1,852,895 in net proceeds during the nine months ended September 30, 2025.
• Strategic partnerships formed for AI Nose deployment, including a three-year subscription-based order valued at $2.1 million with ASE Technology Holding Co., Ltd. for 1,400 AI Nose units.
• Expansion of AI Nose into industrial, robotics, and long-term care environments, with pilot deployments planned in Japan and Taiwan.
• VELDONA formulation received Orphan Drug Designation from the U.S. FDA for oral warts in HIV-seropositive patients.
• Decrease in R&D expenses by 2% in Q3 2025 and 8% for the nine months ended September 30, 2025, when excluding non-cash expenses.
• Decrease in SG&A expenses by 22% in Q3 2025, when excluding non-cash expenses.

Negatives

• Continued net losses, with an accumulated deficit of $(63,052,030) as of September 30, 2025.
• Cash and cash equivalents significantly decreased to $1,128,217 as of September 30, 2025, from $3,892,919 at December 31, 2024.
• Substantial doubt exists about the company's ability to continue as a going concern for at least one year from the issuance of these financial statements.
• Operating loss increased by 5% for the nine months ended September 30, 2025, to $(9,692,751).
• Selling, General and Administrative (SG&A) expenses increased by 35% for the nine months ended September 30, 2025, to $4,159,627.
• Interest expense increased by 24% for the nine months ended September 30, 2025, to $(534,986).
• The company has undergone multiple reverse stock splits (1-for-15 in 2022, 1-for-5 in 2023, 1-for-5 in 2025) to maintain Nasdaq listing, indicating persistent share price challenges.
• Discontinuation of COVID-19 test kits in Q1 2024.

Risks

• Liquidity Risk: Inability to obtain additional financing on acceptable terms, on a timely basis, or at all, which could materially adversely impact business, results of operations, and financial condition.
• Going Concern Risk: Substantial doubt about the company's ability to continue as a going concern for at least one year from the issuance of the financial statements due to accumulated deficit and expected continued losses.
• Product Development Risk: Uncertainty regarding the timing and progress of research and development efforts for AI Nose, POCT, and VELDONA drug candidates.
• Market Acceptance Risk: Uncertainty regarding the commercial success and market adoption of new products and technologies, such as the AI Nose platform.
• Regulatory Risk: Dependence on regulatory approvals (e.g., FDA, TFDA) for therapeutic candidates and POCT devices.
• Intellectual Property Litigation Risk: Operating in an industry characterized by extensive patent litigation, with potential for claims of infringement, significant damage awards, and injunctions.
• Foreign Currency and Exchange Rate Fluctuations: Negative impact on business, results of operations, and financial position due to foreign operations denominated in foreign currencies (e.g., Taiwan Dollar).
• International Trade Policy Changes: Adverse impact on demand for products, competitive position, or ability to sell products due to more restrictive trade policies, tariffs, or new barriers to entry.

Future Outlook

The company expects to continue incurring development expenses for the next twelve months as it advances product development plans for AI Nose, VOC POCT, and VELDONA drug candidates, with R&D expenses anticipated to grow. The near-term priority is scaling the AI Nose platform in industrial, robotics, and long-term care settings through partnerships and a subscription-based model (Smelltech-as-a-Service). Clinical trials for VELDONA's lead indications (HIV-related oral warts and Sjogren's syndrome) are planned in Taiwan, along with pilot deployments for AI Nose in Japan and Taiwan. The company anticipates funding operations over the next twelve months through business revenues and potential external financing, but may reprioritize programs based on funding availability, regulatory progress, or market conditions.

Management Comments

• "We expect that our R&D expenses related to clinical trials will continue to grow as we further develop AI Nose, VOC POCT and VELDONA drug candidates."
• "We continued to invest resources to execute our growth strategy and product roadmap to improve our profitability."
• "Our top near-term priority is scaling the AI Nose platform in industrial, robotics, and long-term care settings, through our partnerships and supported by a subscription-based model that aims to offer AI-driven scent analytics and hardware services."
• "This Smelltech-as-a-Service (SaaS) approach is designed to generate recurring revenue, while we continue targeted, capital-efficient clinical validation of Ainos Flora in Taiwan and explore potential partnerships or licensing opportunities."
• "In parallel, we are advancing select VELDONA programs through cost-effective clinical studies in Taiwan, balancing development progress with capital discipline and exploring potential licensing or partnership opportunities."
• "Although management expects the Company will continue as a going concern, there is no assurance that managements plans will be successful since the availability and amount of such funding is not certain."

Industry Context

Ainos operates at the intersection of artificial intelligence, advanced sensing technology, and healthcare, a rapidly evolving and competitive landscape. The company's focus on AI-powered digital olfaction (AI Nose) aligns with broader industry trends towards integrating advanced sensors in IoT, smart manufacturing, and robotics for enhanced monitoring and predictive analytics. The adoption of a "Smelltech-as-a-Service" model reflects the growing trend of subscription-based solutions in enterprise technology. In healthcare, the development of low-dose oral interferon therapeutics (VELDONA) for rare, autoimmune, and infectious diseases, alongside point-of-care testing (POCT), positions Ainos in a high-growth but capital-intensive sector. Strategic partnerships with entities like ASE Technology Holding Co., Ltd. (semiconductor), ugo, Inc. (robotics), Topco Scientific Co., Ltd. (semiconductor solutions), and Kenmec Mechanical Engineering Co., Ltd. (automation) demonstrate an effort to diversify applications and accelerate commercialization across multiple industries, leveraging the versatility of its AI Nose platform. However, the company's history of repeated reverse stock splits indicates challenges in maintaining investor confidence and market valuation, a common issue for early-stage biotech/AI companies with long development cycles and significant capital needs.

Comparison to Industry Standards

• AI Nose Platform: Ainos's strategy to integrate AI Nose into autonomous robots for environmental monitoring (with ugo, Inc. in Japan) and real-time anomaly detection in semiconductor manufacturing (with ASE Technology Holding Co., Ltd.) positions it in a nascent but high-potential market. Comparable companies in digital olfaction or electronic nose technology include eNose, Aryballe, and Alpha MOS, which are also exploring applications in industrial safety, food quality, and healthcare. Ainos's $2.1 million, three-year subscription order for 1,400 AI Nose units with ASEH is a notable commercial milestone, indicating early market traction in a specialized industrial segment.
• VELDONA Therapeutics: The development of low-dose oral interferon for indications like oral warts in HIV-positive patients and Sjogren's syndrome places Ainos in the biopharmaceutical sector. Orphan Drug Designation from the U.S. FDA for its HIV-related oral warts program is a significant regulatory achievement, comparable to similar designations received by other biotech firms for rare disease treatments, which can accelerate development and provide market exclusivity. However, the company's continued reliance on clinical studies in Taiwan suggests a more localized or early-stage development approach compared to larger pharmaceutical companies conducting global multi-phase trials.
• POCT Devices: The focus on VOC-based POCT devices like Ainos Flora for female vaginal health and CHS430 for ventilator-associated pneumonia aligns with the broader trend towards non-invasive, rapid diagnostics. Companies like LumiraDx, Quidel, and Abbott are leaders in the POCT market, offering a wide range of diagnostic solutions. Ainos's approach, leveraging its AI Nose technology for scent analysis in diagnostics, represents an innovative niche within this competitive space, though it is still in clinical study phases.
• Financial Performance: The company's continued net losses and 'going concern' warning are common for early-stage biotechnology and deep-tech companies that require substantial R&D investment before commercialization. However, the repeated reverse stock splits to maintain Nasdaq listing are a red flag, indicating significant dilution and share price underperformance compared to more stable, established industry players. The cash position of $1.13 million as of September 30, 2025, is relatively low for a company with ongoing R&D and clinical trial expenses, highlighting the urgent need for further capital.

Corporate Governance

Legal Proceedings

• As of the date of this report, the company was not aware of any material legal proceedings involving the Company.

Related Party Transactions

• Convertible Notes Payable: ASE Test, Inc. (a shareholder of Ainos KY) committed $2,000,000 for March 2025 Convertible Notes, with an amendment on March 10, 2025, extending maturity to March 12, 2027, and adjusting conversion price. ASE Test, Inc. also provided $9,000,000 for May 2027 Convertible Notes, payable three years from May 3, 2024. Total related party noncurrent convertible notes payable were $11,000,000 as of September 30, 2025.
• Product Co-development Agreement with TCNT: Development expenses incurred were $84,060 for Q3 2025 and $257,732 for the nine months ended September 30, 2025. Fee for non-exclusive use of patents was $149,504 for Q3 2025 and $457,517 for the nine months ended September 30, 2025. An advance payment of $103,783 was recorded as of September 30, 2025. On October 15, 2025, an addendum amended the fee for exclusive use of patents to $50,000 per month (plus 5% sales tax) for a two-year period starting October 16, 2025.

Stakeholder Impact

• Shareholders: Potential for significant dilution due to ongoing At-the-Market offerings and convertible notes. Repeated reverse stock splits indicate erosion of per-share value and efforts to maintain listing compliance. The 'going concern' warning poses a substantial risk to investment.
• Employees: Share-based compensation is a significant component of R&D and SG&A expenses, indicating a reliance on equity incentives. Continued losses and liquidity issues could impact job security or future compensation.
• Customers: Continued product development in AI Nose, POCT, and VELDONA offers potential new solutions, particularly in industrial, robotics, and healthcare sectors. The $2.1 million subscription order with ASEH indicates a positive impact for that customer.
• Creditors: Convertible note holders, especially related parties like ASE Test, Inc., are significant creditors. The extension of maturity dates on some notes indicates ongoing financial management.
• Suppliers: The company's operations and development expenses involve various suppliers. Liquidity concerns could pose a risk to timely payments if not managed effectively.

Next Steps

• Continue development of AI Nose, VOC POCT, and VELDONA drug candidates.
• Scale the AI Nose platform in industrial, robotics, and long-term care settings through partnerships.
• Pilot deploy service robots equipped with AI Nose at seven industrial sites in Japan.
• Deploy 1,400 AI Nose units across ASEH's three manufacturing sites under a three-year, $2.1 million subscription order.
• Advance VELDONA programs through cost-effective clinical studies in Taiwan for HIV-related oral warts and Sjogren's syndrome.
• Conduct clinical studies in Taiwan for feline chronic gingivostomatitis (FCGS).
• Continue targeted, capital-efficient clinical validation of Ainos Flora in Taiwan.
• Explore potential partnerships or licensing opportunities for Ainos Flora and VELDONA programs.
• Negotiate payment terms and subsequent licensing methods for the exclusive use of patents with TCNT after October 16, 2027.
• Raise additional capital through equity securities, debt financings, or other sources if current financing plans are insufficient.

Key Dates

Recommendation

Despite some promising strategic partnerships and revenue growth in specific segments, the company faces severe liquidity challenges, evidenced by a significant decline in cash and an explicit 'going concern' warning. The persistent net losses, increasing operating losses over nine months, and a history of multiple reverse stock splits to maintain Nasdaq listing indicate fundamental financial instability and a high risk of further shareholder dilution or even delisting. The long development cycles for its core technologies (AI Nose, VELDONA) coupled with its current cash position suggest a high probability of needing substantial additional capital, which may not be available on favorable terms. This combination of factors presents an extremely high-risk profile for investors.

Keywords

AI Nose, Digital Olfaction, Scent Digitization, VOC Sensing, VELDONA, Low-Dose Oral Interferon, POCT, Healthcare AI, Robotics, Smart Manufacturing, Orphan Drug Designation, Reverse Stock Split, Nasdaq Listing, Biotechnology, Pharmaceuticals, Medical Devices